| |
CAMBRIDGE, MA — October 29, 2004 – Momenta
Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing
drugs based on sugar sequencing technology, announced today that its
Chairman and Chief Executive Officer, Alan Crane, will present at the
CIBC World Markets Fifteenth Annual Healthcare Conference on Monday,
November 8, 2004 at 4:30 pm Eastern Standard Time at the Plaza Hotel,
New York, NY. A live webcast of the presentation will be available on
the “Investors” section of the Company’s website located
at www.momentapharma.com. A replay of the presentation will be posted
on the Momenta website approximately five minutes after the event and
will be available through December 8, 2004.
About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing
in the sequencing and engineering of complex sugars for the development
of improved versions of existing drugs, the development of novel drugs
and the discovery of new biological processes. Momenta is also utilizing
its ability to sequence sugars to create technology-enabled generic
products. The Company’s most advanced product candidate is M-Enoxaparin,
a technology-enabled generic version of Lovenox®. Based on its understanding
of complex sugars, Momenta has created a diversified pipeline of novel
discovery and development candidates. Momenta was founded in 2001 and
is headquartered in Cambridge, MA.
To receive additional information about Momenta,
please visit our website at www.momentapharma.com, which does not form
a part of this press release.
Forward Looking Statements
Statements in this press release regarding Momenta Pharmaceuticals Inc.’s
future expectations, beliefs, goals, plans or prospects constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Momenta’s actual results could differ materially
from those stated or implied in forward-looking statements due to a
number of factors, including those factors contained in Momenta’s
final prospectus dated June 21, 2004 filed with the Securities and Exchange
Commission in connection with Momenta’s initial public offering
under the section “Risk Factors,” as well as other documents
that may be filed by Momenta from time to time with the Securities and
Exchange Commission. Forward-looking statements include statements regarding
Momenta’s expectations, beliefs, intentions or strategies regarding
the future and can be identified by forward-looking words such as “anticipate”,
“believe”, “could”, “estimate”,
“expect”, “intend”, “may”, “should”,
“will”, and “would” or similar words. Momenta
assumes no obligations to update the information included in this press
release.
Our logo, trademarks, and service marks are the property
of Momenta Pharmaceuticals, Inc. All other trade names, trademarks,
or service marks are property of their respective owners and are not
the property of Momenta Pharmaceuticals, Inc.
Contact: Momenta Pharmaceuticals, Inc., Valerie Threlfall, 617-395-5116
|
|
Press
Contact
press@momentapharma.com
Company
Fact Sheet
Technology
Fact Sheet
Regulatory
Fact Sheet
|
